MIDATECH PHARMA
R&D | Oncology

GNP Drug Conjugates: Oncology

Midatech aims to improve cancer therapy outcomes based on combining chemotherapeutic or immunotherapeutic agents with tumour-targeting molecules or peptides on the same gold nanoparticle conjugate. The aim is to allow highly toxic drugs to be specifically targeted at/ delivered to the tumour cells while sparing normal tissue, thereby reducing the side effects associated with chemotherapy and enhancing efficacy. At present Midatech is focusing on development of drug candidates for liver hepatocellular carcinoma (HCC) and brain glioblastoma multiforme (GBM) cancer. Other cancers such assquamous cell carcinoma (SCC) of the skin are also being researched.

An essential advantage of the GNP particle is the ability to create a multivalent particle i.e. multiple therapeutic and targeting agents or peptides which can be attached to a single particle, as well as hydrophilic/phobic ligands, and incorporating different charge states. This should allow the particle to solubilize and distribute the active therapeutic agents for targeted release to specific organs, cells or disease sites. Ultimately GNP-drug conjugates can be developed to target specific tumour-types by binding to sites over-expressed in that tumour.

Since the middle of 2013, Midatech has focused its research and development activities on liver and brain cancer. GNP drug conjugates are continually being screened, analysed and evaluated for their targeting and cytotoxic properties.

Further research and development activities are underway by Midatech in relation to sustained release technology for the treatment of cancer. For more information go to our Sustained Release technology section.

R&D
R&D
Oncology

GNP Drug Conjugates: Oncology

Midatech aims to improve cancer therapy outcomes based on combining chemotherapeutic or immunotherapeutic agents with tumour-targeting molecules or peptides on the same gold nanoparticle conjugate. The aim is to allow highly toxic drugs to be specifically targeted at/ delivered to the tumour cells while sparing normal tissue, thereby reducing the side effects associated with chemotherapy and enhancing efficacy. At present Midatech is focusing on development of drug candidates for liver hepatocellular carcinoma (HCC) and brain glioblastoma multiforme (GBM) cancer. Other cancers such assquamous cell carcinoma (SCC) of the skin are also being researched.

An essential advantage of the GNP particle is the ability to create a multivalent particle i.e. multiple therapeutic and targeting agents or peptides which can be attached to a single particle, as well as hydrophilic/phobic ligands, and incorporating different charge states. This should allow the particle to solubilize and distribute the active therapeutic agents for targeted release to specific organs, cells or disease sites. Ultimately GNP-drug conjugates can be developed to target specific tumour-types by binding to sites over-expressed in that tumour.

Since the middle of 2013, Midatech has focused its research and development activities on liver and brain cancer. GNP drug conjugates are continually being screened, analysed and evaluated for their targeting and cytotoxic properties.

Further research and development activities are underway by Midatech in relation to sustained release technology for the treatment of cancer. For more information go to our Sustained Release technology section.

© Copyright 2017 Midatech Pharma PLC